TICKERNERD
Menu
CABACABAHealthcare · Biotechnology

CABA Stock Forecast: Cabaletta Bio, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.75
+1.48% on the day

The 10 Wall Street analysts covering Cabaletta Bio, Inc. hold a median 12-month price target of $14 — +390.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$448.4M
Ticker Nerd rank
27 / 100
Median analyst target
$14
Analysts covering
10
Total return, dividends reinvested
1W
−1.4%
1M
+3.0%
YTD
+25.6%
1Y
+66.7%
From 52W high
−33.7%
From 52W low
+89.7%
$1.45
$4.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CABA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cabaletta Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
68
Growth
57
Size
55
Accruals
53
Revisions
45
Value
27
Quality
26
Volatility
22
Issuance
18

Momentum (68): The shares have been drifting up relative to others.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CABA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CABA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00Oct 25Jan 26Apr 26Jul 26CABAHigh $30Median $14Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $3Median $14High $30

The green dot is the last close — the median target sits +390.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Wells FargoMaintainsEqual-Weight$4.00 → $3.00
15 May 2026Wells FargoMaintainsEqual-Weight$2.00 → $4.00
15 May 2026Wells FargoMaintainsEqual-Weight—
4 May 2026Cantor FitzgeraldReiteratesOverweight—
24 Mar 2026GuggenheimMaintainsBuy—
24 Mar 2026Morgan StanleyMaintainsOverweight—
31 Oct 2025Cantor FitzgeraldMaintainsOverweight—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
5 Sept 2025Cantor FitzgeraldReiteratesOverweight—
14 Aug 2025CitigroupMaintainsBuy—
8 Aug 2025GuggenheimMaintainsBuy—
8 Aug 2025Wells FargoMaintainsEqual-Weight—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025CitigroupMaintainsBuy—
16 May 2025GuggenheimMaintainsBuy—
15 May 2025GuggenheimMaintainsBuy—
1 Apr 2025GuggenheimReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025Morgan StanleyMaintainsOverweight—
1 Apr 2025UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CABA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CABA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Cabaletta Bio, Inc. (CABA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.2%

Higher than 14% of US stocks

Return on assets
−48.2%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CABA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CABACabaletta Bio, Inc.$448.4M
27
PBYIPuma Biotechnology, Inc.$449.4M
99
QTTBQ32 Bio, Inc.$450.9M
86
RZLTRezolute, Inc.$440.2M
34
OCGNOcugen, Inc.$457.0M
25
DNAGinkgo Bioworks Holdings, Inc.$439.8M
49
LRMRLarimar Therapeutics, Inc.$460.4M
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cabaletta Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CABA news & analysis

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Cabaletta Bio reported second quarter 2026 financial results and provided a business update. The company stated that registrational RESET-Myositis clinical data remain on track to be reported in mid-2027, supporting a planned BLA submission for rese-cel in the second half of 2027.

Why it matters — This update confirms that rese-cel, the company's key pipeline candidate, is on schedule for registrational data and a near-term regulatory filing, signaling steady progress toward a potential commercial launch.

FAQ

Frequently asked questions about CABA stock

What is the CABA stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Cabaletta Bio, Inc. have a median 12-month price target of $14, with estimates ranging from $3 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CABA stock a buy right now?

Of the 10 analysts covering Cabaletta Bio, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cabaletta Bio, Inc. 27 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CABA?

As at 15 Aug 2026, Cabaletta Bio, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (68 of 100).

Will CABA stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +390.9% from the last close, and Ticker Nerd's factor model ranks Cabaletta Bio, Inc. 27 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CABA stock forecast for 2030?

No analyst covering Cabaletta Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CABA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $30 over the next 12 months.

How has CABA stock performed over the past year?

Cabaletta Bio, Inc. returned +66.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cabaletta Bio, Inc. do?

Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases.

What is the latest news on CABA?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update". Cabaletta Bio reported second quarter 2026 financial results and provided a business update. The company stated that registrational RESET-Myositis clinical data remain on track to be reported in mid-2027, supporting a planned BLA submission for rese-cel in the second half of 2027.

Company

About Cabaletta Bio, Inc.

Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases. The company focuses on leveraging its proprietary CABA platform, which includes two main approaches: CARTA, or chimeric antigen receptor T cells for autoimmunity, and CAART, or chimeric autoantibody receptor T cells, designed to selectively target disease-causing B cells while preserving normal immune function. Cabaletta Bio’s lead programs are directed at complex autoimmune indications such as dermatomyositis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, and pemphigus vulgaris, reflecting its emphasis on severe, immune-driven disorders with significant unmet medical need. By applying cell therapy concepts that have been validated in oncology to autoimmune disease, Cabaletta Bio occupies a distinct niche at the intersection of immunology and advanced therapeutics. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, the company operates within the healthcare and biotechnology sectors, serving global clinical and research communities developing next-generation treatments for autoimmune conditions.

CEO Dr. Steven A. Nichtberger M.D. · 154 employees · United States · https://www.cabalettabio.com